Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGFΒ signaling

Oncogene

Volumn 30, Issue 28, 2011, Pages 3153-3162

  Knauf, J A ^a   Sartor, M A ^b,d   Medvedovic, M ^b   Lundsmith, E ^a   Ryder, M ^a   Salzano, M ^a   Nikiforov, Y E ^b,e   Giordano, T J ^c   Ghossein, R A ^a   Fagin, J A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

^e UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

BRAF; epithelialmesenchymal transition; TGF ; thyroid

Indexed keywords

B RAF KINASE; MITOGEN ACTIVATED PROTEIN KINASE; RNA; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UVOMORULIN; VIMENTIN;

ANIMAL EXPERIMENT; ARTICLE; CANCER GROWTH; CELL ADHESION; CELL JUNCTION; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; IMMUNOHISTOCHEMISTRY; LASER MICRODISSECTION; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; POORLY DIFFERENTIATED THYROID CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; THYROID CELL; THYROID PAPILLARY CARCINOMA; TRANSCRIPTION INITIATION;

ANIMALS; CATTLE; DISEASE PROGRESSION; ENZYME ACTIVATION; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION PROFILING; HUMANS; MAP KINASE SIGNALING SYSTEM; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; ORGAN SPECIFICITY; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS B-RAF; SMAD2 PROTEIN; THYROID GLAND; THYROID NEOPLASMS; TRANSCRIPTION, GENETIC; TRANSFORMING GROWTH FACTOR BETA;

ANIMALIA; MUS;

EID: 79960381628     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.44     Document Type: Article

References (53)

1. Ball DW, Jin N, Rosen DM, Dackiw A, Sidransky D, Xing M et al. (2007). Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244. J Clin Endocrinol Metab 92: 4712-4718. (Pubitemid 350223448)
2. Benjamini Y, Hochberg Y. (1995). Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B 57: 289-300.
3. Bravo SB, Pampin S, Cameselle-Teijeiro J, Carneiro C, Dominguez F, Barreiro F et al. (2003). TGF-beta-induced apoptosis in human thyrocytes is mediated by p27kip1 reduction and is overridden in neoplastic thyrocytes by NF-kappaB activation. Oncogene 22: 7819-7830. (Pubitemid 37485541)
4. Dai M, Wang P, Boyd AD, Kostov G, Athey B, Jones EG et al. (2005). Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res 33: e175.
5. Depoortere F, Pirson I, Bartek J, Dumont JE, Roger PP. (2000). Transforming growth factor beta(1) selectively inhibits the cyclic AMP-dependent proliferation of primary thyroid epithelial cells by preventing the association of cyclin D3-cdk4 with nuclear p27(kip1). Mol Biol Cell 11: 1061-1076. (Pubitemid 30159322)
6. Derynck R, Zhang YE. (2003). Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 425: 577-584. (Pubitemid 37280136)
7. Elisei R, Ugolini C, Viola D, Lupi C, Biagini A, Giannini R et al. (2008). BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab 93: 3943-3949.
8. Fagin JA, Matsuo K, Karmakar A, Chen DL, Tang SH, Koeffler HP. (1993). High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest 91: 179-184. (Pubitemid 23037270)
9. Franco AT, Malaguarnera R, Refetoff S, Liao XH, Lundsmith E, Kimura S et al. (2011). Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice. Proc Natl Acad Sci USA 108: 1615-1620.
10. Funaba M, Zimmerman CM, Mathews LS. (2002). Modulation of Smad2-mediated signaling by extracellular signal-regulated kinase. J Biol Chem 277: 41361-41368. (Pubitemid 35257436)
11. Giordano TJ, Kuick R, Thomas DG, Misek DE, Vinco M, Sanders D et al. (2005). Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene 24: 6646-6656. (Pubitemid 41486795)
12. Gomis RR, Alarcon C, He W, Wang Q, Seoane J, Lash A et al. (2006). A FoxO-Smad synexpression group in human keratinocytes. Proc Natl Acad Sci USA 103: 12747-12752. (Pubitemid 44298632)
13. Guo J, Sartor M, Karyala S, Medvedovic M, Kann S, Puga A et al. (2004). Expression of genes in the TGF-beta signaling pathway is significantly deregulated in smooth muscle cells from aorta of aryl hydrocarbon receptor knockout mice. Toxicol Appl Pharmacol 194: 79-89. (Pubitemid 38064444)
14. Inoue Y, Imamura T. (2008). Regulation of TGF-beta family signaling by E3 ubiquitin ligases. Cancer Sci 99: 2107-2112.
15. Jechlinger M, Grunert S, Beug H. (2002). Mechanisms in epithelial plasticity and metastasis: insights from 3D cultures and expression profiling. J Mammary Gland Biol Neoplasia 7: 415-432. (Pubitemid 38438259)
16. Kalluri R, Weinberg RA. (2009). The basics of epithelial-mesenchymal transition. J Clin Invest 119: 1420-1428.
17. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. (2003). High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RASBRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63: 1454-1457. (Pubitemid 36373628)
18. Knauf JA, Ma X, Smith EP, Zhang L, Mitsutake N, Liao XH et al. (2005). Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res 65: 4238-4245. (Pubitemid 40775662)
19. Leboeuf R, Baumgartner JE, Benezra M, Malaguarnera R, Solit D, Pratilas CA et al. (2008). BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase inhibition in thyroid cancer cell lines. J Clin Endocrinol Metab 93: 2194-2201. (Pubitemid 351831535)
20. Lee MK, Pardoux C, Hall MC, Lee PS, Warburton D, Qing J et al. (2007). TGF-beta activates Erk MAP kinase signalling through direct phosphorylation of ShcA. EMBO J 26: 3957-3967. (Pubitemid 47367487)
21. Lin X, Liang M, Feng XH. (2000). Smurf2 is a ubiquitin E3 ligase mediating proteasome-dependent degradation of Smad2 in transforming growth factor-beta signaling. J Biol Chem 275: 36818-36822. (Pubitemid 32002092)
22. Mao X, Fujiwara Y, Chapdelaine A, Yang H, Orkin SH. (2001). Activation of EGFP expression by Cre-mediated excision in a new ROSA26 reporter mouse strain. Blood 97: 324-326. (Pubitemid 32061277)
23. Massague J. (2008). TGFbeta in cancer. Cell 134: 215-230.
24. Montero-Conde C, Martin-Campos JM, Lerma E, Gimenez G, Martinez-Guitarte JL, Combalia N et al. (2008). Molecular profiling related to poor prognosis in thyroid carcinoma. Combining gene expression data and biological information. Oncogene 27: 1554-1561. (Pubitemid 351347876)
25. Morris III JC, Ranganathan G, Hay ID, Nelson RE, Jiang NS. (1988). The effects of transforming growth factor-beta on growth and differentiation of the continuous rat thyroid follicular cell line, FRTL-5. Endocrinology 123: 1385-1394.
26. Muller PY, Janovjak H, Miserez AR, Dobbie Z. (2002). Processing of gene expression data generated by quantitative real-time RT-PCR. Biotechniques 32: 1372-1379. (Pubitemid 34619770)
27. Namba H, Nakashima M, Hayashi T, Hayashida N, Maeda S, Rogounovitch TI et al. (2003). Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab 88: 4393-4397. (Pubitemid 37153748)
28. Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F et al. (2003). BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 88: 5399-5404. (Pubitemid 37452745)
29. Padua D, Zhang XH, Wang Q, Nadal C, Gerald WL, Gomis RR et al. (2008). TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell 133: 66-77. (Pubitemid 351442989)
30. Peinado H, Olmeda D, Cano A. (2007). Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer 7: 415-428. (Pubitemid 46809165)
31. Reiner A, Yekutieli D, Benjamini Y. (2003). Identifying differentially expressed genes using false discovery rate controlling procedures. Bioinformatics 19: 368-375. (Pubitemid 36284936)
32. Ricarte-Filho JC, Ryder M, Chitale DA, Rivera M, Heguy A, Ladanyi M et al. (2009). Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res 69: 4885-4893.
33. Riesco-Eizaguirre G, Rodriguez I, De la Vieja A, Costamagna E, Carrasco N, Nistal M et al. (2009). The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer. Cancer Res 69: 8317-8325.
34. Ryder M, Ghossein RA, Ricarte-Filho JC, Knauf JA, Fagin JA. (2008). Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer. Endocr Relat Cancer 15: 1069-1074.
35. Saltman B, Singh B, Hedvat CV, Wreesmann VB, Ghossein R. (2006). Total parenteral nutrition in children and adolescents treated with high-dose chemotherapy followed by autologous haematopoietic transplants. Surgery 140: 899-906.
36. Sartor MA, Leikauf GD, Medvedovic M. (2009). LRpath: a logistic regression approach for identifying enriched biological groups in gene expression data. Bioinformatics 25: 211-217.
37. Sartor MA, Mahavisno V, Keshamouni VG, Cavalcoli J, Wright Z, Karnovsky A et al. (2010). ConceptGen: a gene set enrichment and gene set relation mapping tool. Bioinformatics 26: 456-463.
38. Sartor MA, Tomlinson CR, Wesselkamper SC, Sivaganesan S, Leikauf GD, Medvedovic M. (2006). Intensity-based hierarchical Bayes method improves testing for differentially expressed genes in microarray experiments. BMC Bioinformatics 7: 1-17.
39. Savage ND, de BT, Walburg KV, Joosten SA, van MK, Geluk A et al. (2008). Human anti-inflammatory macrophages induce Foxp3+ GITR+ CD25+ regulatory T cells, which suppress via membranebound TGFbeta-1. J Immunol 181: 2220-2226.
40. Seo SR, Lallemand F, Ferrand N, Pessah M, LHoste S, Camonis J et al. (2004). The novel E3 ubiquitin ligase Tiul1 associates with TGIF to target Smad2 for degradation. EMBO J 23: 3780-3792. (Pubitemid 39389709)
41. Smyth GK. (2004). Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3: 1-25.
42. Soares P, Trovisco V, Rocha AS, Lima J, Castro P, Preto A et al. (2003). BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 22: 4578-4580. (Pubitemid 36920701)
43. Tang B, Vu M, Booker T, Santner SJ, Miller FR, Anver MR et al. (2003). TGF-beta switches from tumor suppressor to prometastatic factor in a model of breast cancer progression. J Clin Invest 112: 1116-1124. (Pubitemid 38056326)
44. Tse JC, Kalluri R. (2007). Mechanisms of metastasis: epithelial- tomesenchymal transition and contribution of tumor microenvironment. J Cell Biochem 101: 816-829. (Pubitemid 47040864)
45. Tsushima T, Arai M, Saji M, Ohba Y, Murakami H, Ohmura E et al. (1988). Effects of transforming growth factor-beta on deoxyribonucleic acid synthesis and iodine metabolism in porcine thyroid cells in culture. Endocrinology 123: 1187-1194.
46. Vasko V, Espinosa AV, Scouten W, He H, Auer H, Liyanarachchi S et al. (2007). Gene expression and functional evidence of epithelialto- mesenchymal transition in papillary thyroid carcinoma invasion. Proc Natl Acad Sci USA 104: 2803-2808. (Pubitemid 46327960)
47. Weinberg RA. (2008). Twisted epithelial-mesenchymal transition blocks senescence. Nat Cell Biol 10: 1021-1023.
48. Wiseman SM, Griffith OL, Deen S, Rajput A, Masoudi H, Gilks B et al. (2007). Identification of molecular markers altered during transformation of differentiated into anaplastic thyroid carcinoma. Arch Surg 142: 717-727. (Pubitemid 47295728)
49. Wrana JL, Attisano L, Carcamo J, Zentella A, Doody J, Laiho M et al. (1992). TGF beta signals through a heteromeric protein kinase receptor complex. Cell 71: 1003-1014.
50. Wrighton KH, Lin X, Feng XH. (2009). Phospho-control of TGF-beta superfamily signaling. Cell Res 19: 8-20.
51. Xie L, Law BK, Chytil AM, Brown KA, Aakre ME, Moses HL. (2004). Activation of the Erk pathway is required for TGF-beta1- induced EMT in vitro. Neoplasia 6: 603-610. (Pubitemid 39411098)
52. Xing M. (2005). BRAF mutation in thyroid cancer. Endocr Relat Cancer 12: 245-262. (Pubitemid 40896444)
53. Xu J, Lamouille S, Derynck R. (2009). TGF-beta-induced epithelial to mesenchymal transition. Cell Res 19: 156-172.